New combo aims to wipe out breast cancer cells before surgery
NCT ID NCT06797635
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 24 times
Summary
This study tests whether adding a new drug (patritumab deruxtecan) to standard chemotherapy and immunotherapy before surgery can eliminate more cancer cells in people with high-risk early-stage triple-negative or hormone-receptor-low breast cancer. About 372 participants will be randomly assigned to different treatment sequences. The main goals are safety and whether the cancer is completely gone at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center ( Site 2401)
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-••••
-
Clinica Universidad de Navarra ( Site 1703)
RECRUITINGMadrid, Madrid, Comunidad de, 28027, Spain
Contact Phone: •••-•••-••••
-
Hospital Universitario Reina Sofia ( Site 1702)
RECRUITINGCórdoba, 14004, Spain
Contact Phone: •••-•••-••••
-
Houston Methodist Hospital ( Site 0022)
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
-
Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
RECRUITINGBadalona, Catalonia, 08916, Spain
Contact Phone: •••-•••-••••
-
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
RECRUITINGBillings, Montana, 59102, United States
Contact Phone: •••-•••-••••
-
Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
RECRUITINGTaipei, 112, Taiwan
Contact Phone: •••-•••-••••
-
National Cheng Kung University Hospital ( Site 2503)
RECRUITINGTainan, 704, Taiwan
Contact Phone: •••-•••-••••
-
Northwest Cancer Specialists (Compass Oncology) ( Site 8003)
RECRUITINGTigard, Oregon, 97223, United States
Contact Phone: •••-•••-••••
-
Orchard Healthcare Research Inc. ( Site 0006)
RECRUITINGSkokie, Illinois, 60077, United States
Contact Phone: •••-•••-••••
-
SCRI Oncology Partners ( Site 7000)
RECRUITINGNashville, Tennessee, 37203, United States
Contact Phone: •••-•••-••••
-
Seoul National University Hospital ( Site 2400)
RECRUITINGSeoul, 03080, South Korea
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 2402)
RECRUITINGSeoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
Taichung Veterans General Hospital ( Site 2502)
RECRUITINGTaichung, 407, Taiwan
Contact Phone: •••-•••-••••
-
Texas Oncology - DFW ( Site 8000)
RECRUITINGDallas, Texas, 75246, United States
Contact Phone: •••-•••-••••
-
UCLA Hematology/Oncology - Parkside ( Site 0021)
RECRUITINGSanta Monica, California, 90404, United States
Contact Phone: •••-•••-••••
-
Virginia Oncology Associates (VOA) ( Site 8001)
RECRUITINGNorfolk, Virginia, 23502, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.